Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Feb. 7, 2025 — Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to ... Personalized Cancer ...

Cancer of the tonsil is a rare type of head and neck cancer. Cancer happens when abnormal cells start to divide and grow in an uncontrolled way. Symptoms often include a painless neck lump and a sore ...